155 related articles for article (PubMed ID: 27529342)
1. Changes of Brain Glucose Metabolism in the Pretreatment Patients with Non-Small Cell Lung Cancer: A Retrospective PET/CT Study.
Zhang W; Ning N; Li X; Niu G; Bai L; Guo Y; Yang J
PLoS One; 2016; 11(8):e0161325. PubMed ID: 27529342
[TBL] [Abstract][Full Text] [Related]
2. Abnormal brain glucose metabolism patterns in patients with advanced non-small-cell lung cancer after chemotherapy:A retrospective PET study.
Yu J; Cao X; Zhou R; Chen Q; Wang Y
Brain Res Bull; 2023 Oct; 202():110751. PubMed ID: 37625525
[TBL] [Abstract][Full Text] [Related]
3. Preliminary study of brain glucose metabolism changes in patients with lung cancer of different histological types.
Li WL; Fu C; Xuan A; Shi DP; Gao YJ; Zhang J; Xu JL
Chin Med J (Engl); 2015 Feb; 128(3):301-4. PubMed ID: 25635423
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients.
Jeong Y; Cho SS; Park JM; Kang SJ; Lee JS; Kang E; Na DL; Kim SE
J Nucl Med; 2005 Feb; 46(2):233-9. PubMed ID: 15695781
[TBL] [Abstract][Full Text] [Related]
7. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
8. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
9. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
10. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
11. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
[TBL] [Abstract][Full Text] [Related]
13. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
Zhai X; Guo Y; Qian X
Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
[TBL] [Abstract][Full Text] [Related]
14. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
Li C; Tian Y; Shen Y; Wen B; He Y
AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
[No Abstract] [Full Text] [Related]
15. Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?
Kernstine KH; Faubert B; Do QN; Rogers TJ; Hensley CT; Cai L; Torrealba J; Oliver D; Wachsmann JW; Lenkinski RE; Malloy CR; Deberardinis RJ
Ann Thorac Surg; 2020 Apr; 109(4):1019-1025. PubMed ID: 31846640
[TBL] [Abstract][Full Text] [Related]
16. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
18. Topography of brain glucose hypometabolism and epileptic network in glucose transporter 1 deficiency.
Akman CI; Provenzano F; Wang D; Engelstad K; Hinton V; Yu J; Tikofsky R; Ichese M; De Vivo DC
Epilepsy Res; 2015 Feb; 110():206-15. PubMed ID: 25616474
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
20. 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
Mapelli P; Bettinardi V; Fallanca F; Incerti E; Compierchio A; Rossetti F; Coliva A; Savi A; Doglioni C; Negri G; Gianolli L; Picchio M
Curr Radiopharm; 2018; 11(1):50-57. PubMed ID: 29119942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]